Time Is Ripe For Global Action On Orphan Biosimilars
Executive Summary
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.
You may also be interested in...
Can Biosimilar Orphans Increase Health System Sustainability In The UK?
Developing biosimilar orphan drugs is fraught with challenges and needs buy-in from regulators, developers, patients and clinicians.
Scotland Okays Funding For Keytruda and Opdivo For Esophageal Cancer, Among Other Drugs
Immunotherapies for esophageal cancer from BMS and MSD are among the medicines that Scotland’s health technology appraisal body has recommended for use on the National Health system.
Is An End To The Combination Therapy Pricing Problem In Sight In The UK?
Indication-based pricing and tackling complications caused by competition law could help the UK catch up with other countries when it comes to market access for combination therapies.